Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
editorial
. 1974 Aug;1(4):281–283. doi: 10.1111/j.1365-2125.1974.tb00252.x

Plasma concentrations of tricyclic antidepressive drugs

M Lader
PMCID: PMC1402437  PMID: 22454878

Full text

PDF
281

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexanderson B., Evans D. A., Sjöqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J. 1969 Dec 27;4(5686):764–768. doi: 10.1136/bmj.4.5686.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Asberg M., Cronholm B., Sjöqvist F., Tuck D. Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J. 1970 Oct 3;4(5726):18–21. doi: 10.1136/bmj.4.5726.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Asberg M., Crönholm B., Sjöqvist F., Tuck D. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J. 1971 Aug 7;3(5770):331–334. doi: 10.1136/bmj.3.5770.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Asberg M., Germanis M. Ophthalmological effects of nortriptyline--relationship to plasma level. Pharmacology. 1972;7(5):349–356. doi: 10.1159/000136309. [DOI] [PubMed] [Google Scholar]
  5. Borgå O., Azarnoff D. L., Forshell G. P., Sjöqvist F. Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol. 1969 Sep;18(9):2135–2143. doi: 10.1016/0006-2952(69)90318-9. [DOI] [PubMed] [Google Scholar]
  6. Braithwaite R. A., Goulding R., Theano G., Bailey J., Coppen A. Plasma concentration of amitriptyline and clinical response. Lancet. 1972 Jun 17;1(7764):1297–1300. doi: 10.1016/s0140-6736(72)91031-8. [DOI] [PubMed] [Google Scholar]
  7. Braithwaite R. A., Widdop B. A specific gas-chromatographic method for the measurement of "steady-state" plasma levels of amitriptyline and nortriptyline in patients. Clin Chim Acta. 1971 Dec;35(2):461–472. doi: 10.1016/0009-8981(71)90222-1. [DOI] [PubMed] [Google Scholar]
  8. Burrows G. D., Davies B., Scoggins B. A. Plasma concentration of nortriptyline and clinical response in depressive illness. Lancet. 1972 Sep 23;2(7778):619–623. doi: 10.1016/s0140-6736(72)93015-2. [DOI] [PubMed] [Google Scholar]
  9. Crammer J. L., Scott B., Rolfe B. Metabolism of 14C-imipramine. II. Urinary metabolites in man. Psychopharmacologia. 1969;15(3):207–225. doi: 10.1007/BF00411170. [DOI] [PubMed] [Google Scholar]
  10. DINGELL J. V., SULSER F., GILLETTE J. R. SPECIES DIFFERENCES IN THE METABOLISM OF IMIPRAMINE AND DESMETHYLIMIPRAMINE (DMI). J Pharmacol Exp Ther. 1964 Jan;143:14–22. [PubMed] [Google Scholar]
  11. Kragh-Sørensen P., Asberg M., Eggert-Hansen C. Plasma-nortriptyline levels in endogenous depression. Lancet. 1973 Jan 20;1(7795):113–115. doi: 10.1016/s0140-6736(73)90192-x. [DOI] [PubMed] [Google Scholar]
  12. Moody J. P., Tait A. C., Todrick A. Plasma levels of imipramine and desmethylimipramine during therapy. Br J Psychiatry. 1967 Feb;113(495):183–193. doi: 10.1192/bjp.113.495.183. [DOI] [PubMed] [Google Scholar]
  13. Walter C. J. Clinical significance of plasma imipramine levels. Proc R Soc Med. 1971 Mar;64(3):282–285. doi: 10.1177/003591577106400322. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES